Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
Category: #health  | By Nikita Chaurasia  | Date: 2020-01-17 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycoform of mucin 1) CAR-T (chimeric antigen receptor T-cell) therapy in TnMUC1-positive advanced cancers patients.

This clinical trial is assessing CART-TnMUC1 in patients who are suffering from TnMUC1 positive refractory tumors together with a lymphodepletion chemotherapy regimen. The main aim of this trial is to create safety and the suggested Phase 2 dose of CART-TnMUC1 which can be administered with lymphodepletion.

The clinical trial is presently open to patients who are TnMUC1-positive and have treatment-resistant solid tumors comprising pancreatic ductal adenocarcinoma, metastatic ovarian cancer (involving cancers of the fallopian tube), non-small cell lung cancer, and HR (hormone receptor)-negative and HER2-negative TNBC.

Usman Azam, MD, CEO and President of Tmunity, said that the commencement of the first trial to dose patients with a CART-TnMUC1 is a vital milestone not only for the company but also for the oncology community.

This clinical trial marked the third program from the company’s portfolio to enter the clinical testing phase since its inception in 2015. The company is looking forward to advancing its portfolio of novel cell therapies for unmet demand in solid tumors and strengthening the potential for CAR-T therapeutics, he said.

This therapy was created by a University of Pennsylvania team led by Avery D. Posey, Ph.D., an Asst. Professor of Pharmacology and a member of the University’s Abramson Cancer Center.

Speaking on the trial, Posey said that the key challenge in the field of CAR-T cells is to aim solid tumors and hope to potentially discovery a novel therapeutic approach. With an aim to create more effective cancer therapy, they are testing sweet CARs for targeting a sugar that is expressed in tumor cells, claims Posey.

Source Credit - https://www.biospace.com/article/releases/tmunity-announces-first-patient-dosed-in-phase-1-clinical-trial-with-cart-tnmuc1/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...

Legato opens 80 new jobs in its Limerick Research & Development hub

Legato opens 80 new jobs in its Limerick Research & Development hub

By Nikita Chaurasia

The global capability center of a leading U.S. health care insurance company, Legato Health Technologies is planning to build an additional 80 posts at its Limerick facility. It would bring the total number of staff to 200, which the fir...